Janus Henderson Group PLC Has $166.08 Million Holdings in DexCom, Inc. $DXCM

Janus Henderson Group PLC grew its position in DexCom, Inc. (NASDAQ:DXCM) by 32.3% in the first quarter, Holdings Channel reports. The fund owned 2,644,539 shares of the medical device company’s stock after acquiring an additional 645,534 shares during the quarter. Janus Henderson Group PLC’s holdings in DexCom were worth $166,077,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DXCM. Trust Co. of Vermont grew its stake in shares of DexCom by 14.8% in the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after buying an additional 145 shares during the period. V Square Quantitative Management LLC grew its stake in shares of DexCom by 1.8% in the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock worth $604,000 after acquiring an additional 172 shares in the last quarter. Essex Financial Services Inc. increased its stake in DexCom by 5.7% in the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock valued at $204,000 after buying an additional 175 shares during the last quarter. Keel Point LLC increased its position in shares of DexCom by 3.1% during the fourth quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock valued at $430,000 after acquiring an additional 193 shares during the last quarter. Finally, Integrated Wealth Concepts LLC increased its position in shares of DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom News Roundup

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom reported second-quarter adjusted earnings of $0.70 per share, above the $0.61 analyst consensus and up from $0.48 a year earlier. Revenue increased 13.1% year over year to $1.31 billion, exceeding estimates of $1.29 billion. DexCom Q2 earnings and revenues top estimates
• Positive Sentiment: Management raised its fiscal 2026 revenue outlook to $5.2 billion-$5.3 billion, broadly above the roughly $5.2 billion consensus, citing sustained demand for its continuous glucose monitoring systems. DexCom raises annual revenue forecast on strong demand for glucose monitors
• Positive Sentiment: UBS reaffirmed a Buy rating and set a $96 price target, implying substantial upside from recent trading levels. Other analysts have also maintained favorable ratings, with a reported consensus target near $85.40. UBS reaffirms Buy rating
• Neutral Sentiment: The results point to continuing growth in CGM demand, but DexCom trades at a relatively high earnings multiple. Investors may focus on whether the upgraded outlook can justify the valuation following the stock’s rebound.
• Negative Sentiment: Insider Kevin Sayer sold 26,756 shares worth approximately $2.04 million under a pre-arranged Rule 10b5-1 plan. The scheduled transaction reduces his holdings by 7.52%, although it does not necessarily signal a change in the company’s outlook. DexCom insider share sale
• Negative Sentiment: A law firm solicited shareholders regarding potential fiduciary-duty claims involving DexCom insiders. The notice contains no established finding of wrongdoing, but such litigation-related headlines can add short-term uncertainty. DexCom shareholder litigation notice

Wall Street Analyst Weigh In

Several brokerages have issued reports on DXCM. Stifel Nicolaus set a $90.00 target price on DexCom and gave the company a “buy” rating in a research note on Friday, June 5th. Weiss Ratings lowered DexCom from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday. UBS Group set a $96.00 price objective on shares of DexCom and gave the company a “buy” rating in a research report on Tuesday. Sanford C. Bernstein set a $77.00 target price on DexCom in a research note on Friday, May 1st. Finally, Piper Sandler reissued an “overweight” rating and issued a $88.00 target price (up from $75.00) on shares of DexCom in a research note on Monday, June 15th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $84.71.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $74.54 on Friday. The business has a 50-day simple moving average of $72.91 and a two-hundred day simple moving average of $69.10. The firm has a market cap of $28.76 billion, a price-to-earnings ratio of 31.85, a price-to-earnings-growth ratio of 1.24 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $87.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. The business had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company’s quarterly revenue was up 13.1% on a year-over-year basis. During the same period last year, the firm earned $0.48 earnings per share. On average, analysts expect that DexCom, Inc. will post 2.57 earnings per share for the current year.

Insider Activity at DexCom

In other DexCom news, EVP Jon Coleman sold 4,911 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $74.13, for a total transaction of $364,052.43. Following the transaction, the executive vice president directly owned 95,450 shares in the company, valued at $7,075,708.50. This trade represents a 4.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the sale, the executive vice president owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. This represents a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 98,506 shares of company stock valued at $7,205,258 over the last ninety days. 0.28% of the stock is currently owned by company insiders.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.